BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1747 related articles for article (PubMed ID: 31560247)

  • 21. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
    Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE
    Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China.
    Ren Y; Zhao M; Zhou D; Xing Q; Gong F; Tang W
    Front Public Health; 2022; 10():952378. PubMed ID: 36033786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness and projected national impact of colorectal cancer screening in France.
    Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
    Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of Screening Colonoscopy in Iranian High Risk Population.
    Javadinasab H; Daroudi R; Salimzadeh H; Delavari A; Vezvaie P; Malekzadeh R
    Arch Iran Med; 2017 Sep; 20(9):564-571. PubMed ID: 29048918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies.
    Barichello S; Deng L; Ismond KP; Loomes DE; Kirwin EM; Wang H; Chang D; Svenson LW; Thanh NX
    Int J Colorectal Dis; 2019 Nov; 34(11):1953-1962. PubMed ID: 31673772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.
    Phisalprapa P; Supakankunti S; Charatcharoenwitthaya P; Apisarnthanarak P; Charoensak A; Washirasaksiri C; Srivanichakorn W; Chaiyakunapruk N
    Medicine (Baltimore); 2017 Apr; 96(17):e6585. PubMed ID: 28445256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
    Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
    Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia.
    Naber SK; Almadi MA; Guyatt G; Xie F; Lansdorp-Vogelaar I
    Saudi J Gastroenterol; 2021; 27(4):208-216. PubMed ID: 33835054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
    Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
    Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
    Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.
    Aronsson M; Carlsson P; Levin LÅ; Hager J; Hultcrantz R
    Br J Surg; 2017 Jul; 104(8):1078-1086. PubMed ID: 28561259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colorectal cancer screening for average-risk North Americans: an economic evaluation.
    Heitman SJ; Hilsden RJ; Au F; Dowden S; Manns BJ
    PLoS Med; 2010 Nov; 7(11):e1000370. PubMed ID: 21124887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
    Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
    J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis.
    Meester RGS; Lansdorp-Vogelaar I; Winawer SJ; Zauber AG; Knudsen AB; Ladabaum U
    Ann Intern Med; 2019 Nov; 171(9):612-622. PubMed ID: 31546257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the preferences and willingness-to-pay for colorectal cancer screening: an opportunity to incorporate the perspective of population at risk into policy development in Thailand.
    Phisalprapa P; Ngorsuraches S; Wanishayakorn T; Kositamongkol C; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2021; 24(1):226-233. PubMed ID: 33467947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 88.